Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference
01 oct. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference
30 sept. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Pricing of Public Offering of Common Stock
17 sept. 2019 21h06 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Proposed Public Offering of Common Stock
17 sept. 2019 16h01 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing
12 sept. 2019 16h05 HE
|
Translate Bio, Inc.
-- Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE)...
Translate Bio Announces Pipeline Program Update
09 sept. 2019 16h05 HE
|
Translate Bio, Inc.
- Prioritizing and expanding pulmonary disease programs based on early positive cystic fibrosis (CF) data for MRT5005, the first inhaled mRNA therapeutic – - Discontinuing development of MRT5201, a...
Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update
31 juil. 2019 06h51 HE
|
Translate Bio, Inc.
-- Announced interim results from single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis (CF) -- -- Received FDA clearance to advance 2nd program into clinical development,...
Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
31 juil. 2019 06h50 HE
|
Translate Bio, Inc.
-- MRT5005 was generally well tolerated at low and mid-dose levels; no serious adverse events reported at any dose level -- -- Marked increases in ppFEV1 (percent predicted forced expiratory volume...
Translate Bio Appoints George Demetri, M.D., to its Board of Directors
15 juil. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency
26 juin 2019 07h00 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...